Acceptable incremental cost effectiveness ratio for use of new drugs, cases in statin therapies.
Yakugaku Zasshi
; 130(10): 1347-52, 2010 Oct.
Article
em En
| MEDLINE
| ID: mdl-20930487
ABSTRACT
As it is an urgent issue to contain increasing healthcare expenditures, unlimited reimbursement of pharmaceuticals continues to be controversial. The objective of this study is to identify acceptable incremental cost effectiveness ratios between new and conventional therapies. Clinical study data for five statin therapies were used to indicate treatment effectiveness and incremental costs were indicated by price premiums at price listing. The incremental cost effectiveness ratios to pravastatin were 0 yen/patient with response, 1,475.1 yen/patient with response, 3,033.3 yen/patient with response, and 3,032.4 yen/patient with response. By conducting further analyses in various pharmaceuticals and categorizing acceptable incremental cost effectiveness ratios based on the disease severity and expected level of improvement in disease condition, drug prices that reflect the value of new pharmaceuticals and that are reasonable to be reimbursed can be suggested.
Buscar no Google
Coleções:
01-internacional
Temas:
Acesso_medicamentos_insumos_estrategicos
Contexto em Saúde:
1_ASSA2030
Base de dados:
MEDLINE
Assunto principal:
Pravastatina
/
Análise Custo-Benefício
/
Inibidores de Hidroximetilglutaril-CoA Redutases
/
Uso de Medicamentos
/
Reembolso de Seguro de Saúde
/
Seguro de Serviços Farmacêuticos
Tipo de estudo:
Health_economic_evaluation
Limite:
Humans
Idioma:
En
Revista:
Yakugaku Zasshi
Ano de publicação:
2010
Tipo de documento:
Article